Chargement en cours...
Compensatory angiogenesis and tumor refractoriness
Since the establishment of tumor angiogenesis as a therapeutic target, an excitement in developing the anti-angiogenic agents was resulted in tailoring a humanized monoclonal antibody (Bevacizumab) against vascular endothelial growth factor (VEGF): a key factor in recruiting angiogenesis. The past t...
Enregistré dans:
| Publié dans: | Oncogenesis |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4753522/ https://ncbi.nlm.nih.gov/pubmed/26029827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2015.14 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|